The Kidney-Heart Connection in Men: What Creatinine Misses

The relationship between declining kidney function and cardiovascular disease is bidirectional and compounding. Damaged kidneys drive hypertension, anemia, fluid retention, and accelerated atherosclerosis; damaged hearts reduce renal perfusion and drive tubular injury. In men, the trajectory of kidney disease is shaped by male-specific exposures: hypertension that goes undetected longer, more frequent NSAID use, higher rates of obstructive uropathy and gout-related hyperuricemia, and the potential effect of exogenous androgens. These exposures sit upstream of the CKD diagnosis itself, meaning that by the time a man’s kidney disease is identified, the cardiovascular consequences may have been accumulating for years.

Understanding the cardiorenal axis in men requires moving beyond the creatinine-centric view of kidney function that often dominates clinical assessment. Creatinine is a lagging indicator, particularly in men, and by the time it rises visibly, the intersection of cardiac and renal injury is already well established.

The scale of the problem in men is significant. Hypertensive nephrosclerosis and diabetic nephropathy are the leading causes of CKD in men in developed countries, and both conditions carry substantial cardiovascular risk independently of each other. When they coexist with declining kidney function, the cardiac risk is multiplicative rather than additive. Men with CKD at any stage have higher rates of cardiovascular mortality than men without CKD, independent of traditional cardiovascular risk factors, a finding that has been consistent across multiple large cohort studies and that underpins the clinical imperative to treat the cardiorenal axis as an integrated system rather than two separate organ problems.

Why Men’s CKD Looks Different

Men have higher GFR earlier in life, partly due to greater muscle mass, which generates more creatinine production, and partly due to genuinely higher filtration capacity. Men lose GFR faster with age than women in many cohort studies, particularly men with hypertension or metabolic syndrome. This means that a man’s age-related GFR trajectory is steeper than a woman’s on average, and that the cardiovascular consequences of declining kidney function accumulate faster in men who have the primary risk drivers of hypertension and metabolic disease.

By the time serum creatinine rises above 1.2 mg/dL in a large muscular man, eGFR may have already declined substantially. Creatinine is a lagging indicator when muscle mass is high because the same kidney with lower GFR will produce a more normal-appearing creatinine in a man who generates more creatinine from his muscle mass. Conversely, in a frail older man who has lost muscle mass, creatinine may appear normal despite significant GFR loss. The same problem exists in women, but in men it is frequently overlooked because the clinical heuristic that “men have high creatinine” is applied to elderly or ill men for whom that heuristic does not hold.

Cystatin C is a more accurate GFR marker in the setting of abnormal muscle mass, as it is not produced by muscle and is therefore not subject to the creatinine confounding that affects very muscular or very frail men. Calculating eGFR using cystatin C, or a cystatin-C-combined equation, in men at the extremes of muscle mass improves the accuracy of kidney function assessment substantially. The CKD-EPI creatinine-cystatin C combined equation is increasingly available and is preferred when accurate GFR assessment matters for treatment decisions.

The quantitative relationship between eGFR and CV event risk was established across both sexes in foundational work showing that eGFR below 60 is associated with a graded increase in coronary heart disease, heart failure, and stroke risk independent of traditional risk factors. 5 / Solid The risk gradient is continuous; there is no threshold below which kidney function decline is cardiovascularly neutral. Even mild CKD (eGFR 60 to 75) is associated with measurably higher cardiovascular risk than preserved GFR, which means that men in the “normal” eGFR range but trending downward over time warrant closer monitoring than men with stable eGFR in the same numerical range.

Hypertensive Nephrosclerosis: The Primary Male Pathway

Hypertensive nephrosclerosis, glomerular damage from chronic uncontrolled systemic hypertension, is the leading cause of CKD in men after diabetic nephropathy. The mechanism is afferent arteriolar sclerosis driven by sustained systemic pressure, which transmits into the glomerulus, causing glomerular hypertension and eventually irreversible glomerulosclerosis. The damage is largely silent and accumulates over years before creatinine rises, which means men who appear renally normal on creatinine alone may already carry substantial nephron loss.

Men develop hypertension earlier than women; most men are hypertensive by age 55, while most women reach that threshold by age 65. Men are less likely than women to attend blood pressure screening, less likely to be adherent to antihypertensive therapy, and more likely to have years of borderline-to-moderate hypertension (systolic 130 to 145 mmHg) that remains untreated because the individual readings appear to be on the lower end of the high range and do not generate a sense of urgency in either the patient or the clinician.

Years of borderline hypertension produce gradual glomerular hypertension and afferent arteriolar sclerosis even at blood pressure levels that might be considered mild. A man with 15 years of systolic pressure consistently in the 138 to 148 mmHg range may have developed substantial nephrosclerosis by the time his pressure is formally addressed. This is the trajectory that produces the middle-aged or older man who presents for a cardiac evaluation, is found to have an eGFR of 55, and has no clear renal disease history because his kidney function was never closely tracked during the years of borderline hypertension.

The clinical implication is important: in a man with long-standing hypertension, even apparently controlled blood pressure, checking urine albumin-to-creatinine ratio (ACR) alongside eGFR is more informative than eGFR alone. Proteinuria may precede GFR loss by years, and an elevated ACR in a man with normal creatinine reveals early glomerular injury that is not yet apparent from GFR. This is an intervention window; ACE inhibitor or ARB therapy at this stage can reduce proteinuria, slow GFR decline, and reduce the cardiovascular risk associated with early CKD before it progresses to a point where options narrow.

Hyperuricemia, Gout, and Kidney Disease

Gout is a predominantly male disease, with an approximately 4 to 1 sex ratio. Hyperuricemia, defined as uric acid above 7 mg/dL in men, is a marker of both metabolic syndrome and early CKD. Urate is retained as GFR falls, worsening hyperuricemia in a reinforcing cycle where each worsening of kidney function produces higher urate levels, which in turn further impair kidney function through mechanisms that include tubulointerstitial inflammation and direct endothelial toxicity.

Uric acid promotes endothelial dysfunction through direct oxidative effects and reduction in nitric oxide bioavailability, independently contributing to hypertension and CKD progression. This is not merely a bystander effect; experimental and observational evidence shows that uric acid is causally involved in the hypertension-kidney disease cycle rather than simply reflecting it, though the evidence for urate-lowering therapy as a kidney-protective intervention is still developing.

Whether urate-lowering therapy reduces cardiovascular events in men with CKD and hyperuricemia is under study. The CARES trial compared febuxostat with allopurinol and showed non-inferiority for cardiovascular outcomes overall, but identified a signal for increased cardiovascular mortality with febuxostat specifically in patients with established cardiovascular disease, leading to prescribing caution in that subgroup. Allopurinol remains a preferred agent in men with gout and established CVD. The practical priority in men with CKD is to identify hyperuricemia as a modifiable factor and to address it, even if the cardiovascular outcomes evidence for urate-lowering is not yet complete.

Diet modification to reduce purine intake (limiting red meat, organ meats, shellfish, and high-fructose beverages), reducing alcohol, and improving hydration are first-line approaches to hyperuricemia that also benefit kidney function and cardiovascular risk through multiple pathways. In men with frequent gout attacks and persistent hyperuricemia above 9 mg/dL, urate-lowering therapy with allopurinol is generally warranted regardless of the cardiovascular outcomes evidence, since recurrent gout attacks themselves represent inflammatory events with systemic consequences.

NSAIDs, the Gym, and Acute Kidney Injury

Men are more likely than women to use over-the-counter NSAIDs (ibuprofen, naproxen, diclofenac) for musculoskeletal injuries, post-exercise soreness, or chronic musculoskeletal pain. NSAIDs inhibit prostaglandin-mediated afferent arteriolar vasodilation, which is the mechanism by which the kidney autoregulates glomerular filtration during states of reduced perfusion. In men with volume depletion from exercise, heat exposure, or inadequate hydration, or in men with CKD or concurrent ACE inhibitor or ARB use, NSAID use can precipitate acute kidney injury through impairment of this prostaglandin-dependent autoregulation.

The “triple whammy” of ACE inhibitor or ARB plus diuretic plus NSAID is a well-recognized cause of acute kidney injury in older men with hypertension and early CKD. The combination is particularly dangerous because the ACE inhibitor or ARB reduces efferent arteriolar tone (reducing intraglomerular pressure, which is protective in the long run but reduces filtration reserve), the diuretic reduces volume, and the NSAID removes the prostaglandin-mediated afferent dilation that would otherwise compensate. The result is an acute reduction in GFR that can be severe and, in vulnerable men, may not fully recover to baseline.

Athletes with heavy training loads who use NSAIDs regularly for recovery are a specific at-risk group, particularly men who train in heat with intermittent dehydration. Recurrent episodes of NSAID-related AKI, even when creatinine normalizes, may leave permanent nephron loss because some glomeruli lost during each episode are not replaced. The accumulated injury from multiple episodes of “mild” AKI is not fully reversible and contributes to the gradual GFR decline that becomes CKD over time.

The clinical message for men in this situation is to avoid NSAID use during periods of volume depletion or illness, to consider acetaminophen as an alternative for acute pain management, and to discuss the AKI risk explicitly with any man on ACE inhibitor or ARB therapy who is also taking regular NSAIDs. This interaction is frequently undiscussed at prescribing because the NSAID is obtained over the counter without physician involvement, making it invisible to the prescribing record unless the clinician specifically asks.

Anabolic Steroids and Kidney Damage

Exogenous anabolic androgenic steroids, whether prescribed testosterone at supraphysiologic doses or illicitly obtained compounds, cause focal segmental glomerulosclerosis (FSGS) through hemodynamic and direct toxic mechanisms. The proposed mechanism involves increased kidney workload from elevated muscle mass combined with direct toxic effects of androgens on podocytes, the specialized cells that maintain the glomerular filtration barrier. FSGS typically presents as proteinuria; the degree of proteinuria correlates with the cumulative steroid exposure in men who have used AAS for years.

Men who have used anabolic-androgenic steroids for extended periods (typically years to decades, as seen in bodybuilding communities) may present to cardiology with hypertrophic cardiomyopathy from AAS-induced cardiac remodeling and simultaneously to nephrology with CKD from FSGS. This is a clinically relevant pattern in men who were active in competitive bodybuilding, strength sports, or military occupations with access to these compounds and who are now presenting in their 40s and 50s with both cardiac and renal consequences.

Cessation of AAS can stabilize but does not always fully reverse FSGS. The cardiac remodeling from AAS is also partially reversible with cessation, though the degree of recovery depends on the duration and type of use. Identifying AAS use history requires direct clinical questioning, as men are often not forthcoming with this history absent direct inquiry, and the consequences of missing this diagnosis include failure to identify the cause of both the cardiac and renal pathology and missed opportunity for early intervention.

Cardiorenal Syndrome in HFrEF

Heart failure with reduced ejection fraction (HFrEF) is the dominant heart failure phenotype in men, driven by the higher prevalence of ischemic cardiomyopathy and hypertensive cardiomyopathy in men compared to women. In HFrEF, reduced cardiac output leads to reduced renal perfusion, which produces pre-renal acute kidney injury in the setting of acute decompensation (cardiorenal syndrome type 1) and a chronic steady-state reduction in eGFR in stable chronic HF (cardiorenal syndrome type 2).

Managing diuresis in HFrEF men requires balancing decongestion against eGFR decline. Creatinine typically rises with aggressive diuresis even when the patient is clinically improving, because decongestion reduces the elevated filling pressures that were partially compensating for reduced cardiac output, temporarily reducing renal perfusion before cardiac function improves. Rising creatinine during diuresis of a congested HFrEF patient is often not a reason to stop diuretics; it reflects hemodynamic changes more than true nephron loss, and stopping diuretics prematurely in a still-congested patient produces worse long-term renal outcomes than tolerating the transient creatinine rise.

The clinical skill in managing cardiorenal syndrome in HFrEF men lies in distinguishing transient hemodynamic creatinine rise from true tubular injury or worsening renal function that requires response. Urine sodium, fractional excretion of sodium, and urine specific gravity can help distinguish pre-renal hemodynamic changes from intrinsic renal injury, though these distinctions are not always clean in a patient who has both components simultaneously.

SGLT2 inhibitors reduce hospitalization and cardiovascular death in HFrEF and also carry direct renal protective effects independent of the heart failure benefit. The DAPA-HF trial enrolled 4,744 patients and showed a 26 percent reduction in worsening heart failure or cardiovascular death with dapagliflozin. 5 / Solid The mechanisms of renal benefit in HFrEF include reduction in glomerular hyperfiltration, osmotic diuresis that reduces congestion without renin-angiotensin activation, and direct tubular protective effects.

SGLT2 Inhibitors: The Men’s Data

The renal and cardiorenal evidence for SGLT2 inhibitors is particularly strong, and men make up the majority of participants in the key trials, which makes the data directly applicable to clinical decision-making in men with CKD, diabetes, and heart failure.

The CREDENCE trial tested canagliflozin in patients with type 2 diabetes and CKD (eGFR 30 to 90, with significant proteinuria) and found a 30 percent reduction in the composite renal endpoint of doubling of serum creatinine, end-stage kidney disease, or renal or cardiovascular death. Sex-disaggregated data showed consistent benefit in men. 5 / Solid

The DAPA-CKD trial tested dapagliflozin in patients with CKD regardless of diabetes status (eGFR 25 to 75, with proteinuria) and found a 39 percent reduction in the composite of sustained decline in eGFR of 50 percent or more, end-stage kidney disease, or death from renal or cardiovascular causes. Men comprised approximately 67 percent of the trial enrollment, making this dataset particularly informative for male-specific clinical decisions. 5 / Solid

The EMPA-KIDNEY trial tested empagliflozin in 6,609 patients with CKD including many without diabetes, and found a 28 percent reduction in kidney disease progression or cardiovascular death. Men comprised approximately 63 percent of the cohort. 5 / Solid

One important practical point for men initiating SGLT2 inhibitors: an initial eGFR dip of 3 to 5 points is expected and reversible. It reflects reduced glomerular hyperfiltration (a beneficial hemodynamic effect) rather than nephrotoxicity, and the long-term trajectory of eGFR on SGLT2 inhibitors is slower decline than on comparator. Men who have an initial creatinine bump after starting a SGLT2 inhibitor should not have the drug discontinued on that basis; this is a feature of the mechanism, not a safety signal.

Urological Obstruction as a CKD Driver in Older Men

Benign prostatic hyperplasia (BPH) is present in approximately 50 percent of men over 50 and 90 percent of men over 80. Chronic bladder outlet obstruction from BPH causes elevated post-void residual urine volume, which increases bladder pressure and can ultimately produce obstructive nephropathy with hydronephrosis. This is a cause of CKD in older men that does not appear on standard cardiovascular risk factor lists but is identifiable with straightforward non-invasive assessment.

Untreated obstructive uropathy compounds hypertensive nephrosclerosis and accelerates the CKD-CVD progression in older men. The kidney function impairment from chronic obstruction may appear gradual and be attributed to age-related GFR decline rather than to an anatomically correctable cause. Identifying BPH-driven obstructive nephropathy matters because urological treatment, including medical therapy with alpha-blockers or 5-alpha-reductase inhibitors and, when indicated, surgical decompression, can halt or reverse the obstructive component of GFR decline.

For a man over 60 with eGFR decline and no obvious explanatory cause, renal ultrasound looking for hydronephrosis and a post-void residual urine measurement are appropriate next steps. A post-void residual above 100 to 150 mL is clinically significant and warrants urological evaluation. This evaluation is often omitted in a cardiology or nephrology workup focused on glomerular disease, hypertension, or diabetes, but the prevalence of BPH in older men makes it a relevant diagnostic consideration that can change management.

ACE Inhibitors and ARBs in Men with CKD

Both ACE inhibitors and ARBs are Class I indications for proteinuric CKD, independent of whether hypertension is present. They reduce intraglomerular pressure by dilating the efferent arteriole, which slows GFR decline and reduces proteinuria through a mechanism that is partly independent of their systemic blood pressure effect. The renoprotective benefit is present even in men with controlled blood pressure and is specifically related to proteinuria reduction; men with ACR above 300 mg/g benefit most from this mechanism.

Men have lower ACE inhibitor cough rates than women, approximately 5 percent compared to 10 to 15 percent in women, because the bradykinin accumulation responsible for ACE-inhibitor cough appears to be modulated by estrogen. ACE inhibitors are therefore usually the preferred first-line choice in men with CKD and proteinuria, with ARBs as an effective alternative when cough occurs or is anticipated. The clinical effectiveness of the two classes is equivalent for renoprotection.

Hyperkalemia is a real risk in men with CKD Stage 3b to 4 on ACE inhibitor or ARB therapy, particularly men with high dietary potassium intake. Men often have higher caloric intake than women and may consume more potassium-dense foods (legumes, leafy greens, potatoes) in the context of diets designed to support muscle mass or athletic performance. Potassium monitoring is standard after initiation or dose increase of ACE inhibitor or ARB therapy in men with CKD, and diet counseling on potassium sources is appropriate when hyperkalemia is identified. The combination of ACE inhibitor or ARB therapy with a high-protein diet in men focused on muscle maintenance can also worsen hyperkalemia through increased protein-associated acid load; nutrition and medication decisions intersect in this population in ways that require integrated management.

Synthesis: The Integrated Cardiorenal Approach in Men

The cardiorenal connection in men is not simply about two organ systems interacting. It is about a set of male-specific exposures, hypertension detected late and treated inconsistently, NSAID use, gout and hyperuricemia, potential AAS exposure, and urological obstruction in older age, that produce a kidney disease trajectory which in turn amplifies cardiovascular risk in ways that standard risk calculators do not capture.

The practical clinical implication is that cardiovascular risk assessment in men should include kidney function evaluation as a standard component, not an afterthought. eGFR alone is insufficient; ACR should accompany it, particularly in men with hypertension, diabetes, metabolic syndrome, or any history of the exposures described above. When CKD is present, even at mild stages, cardiovascular risk management should be intensified accordingly, because the CKD itself adds a cardiovascular risk burden that sits on top of and interacts with all the traditional risk factors.

SGLT2 inhibitors now provide a treatment option that addresses both kidneys and heart simultaneously, with trial evidence across multiple CKD phenotypes and HFrEF that is directly relevant to male patients who make up the majority of both trial populations and the clinical population with cardiorenal disease. Implementing this evidence requires identifying the men who qualify, which in turn requires the CKD assessment that is still inconsistently performed in practice.

The man who leaves his annual cardiovascular assessment with an eGFR of 58 and no ACR measurement, no urological screening, no NSAID discussion, and no assessment of urate has had an incomplete cardiorenal evaluation, even if his lipids and blood pressure are addressed. Closing that gap requires treating the kidney-heart axis in men as the integrated clinical system that the biology reflects, rather than addressing each organ in isolation when its dysfunction becomes severe enough to demand attention on its own terms.

The Signal Check is fifteen questions mapping the male cardiovascular risk pattern, including the physiological domains most commonly missed in standard screenings. It produces a specific starting point for your next clinical conversation.